Table 3.
Cox proportional hazards regression models for the predictors of RFS and OS in the training set.
| Variables | Univariate analyses | Multivariate analyses | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| RFS | ||||
| Sex (male vs female) |
0.537 (0.235–1.227) | 0.140 | ||
| Location (left/right colon/rectum) |
1.144 (0.682–1.918) | 0.610 | ||
| Age >60 vs ≤60 |
2.020 (0.949–4.298) | 0.068 | ||
| Tumor grade (G3/G2/G1) |
1.730 (0.901–3.322) | 0.100 | ||
| MMR (dMMR vs pMMR) |
0.420 (0.100-1.775) | 0.238 | ||
| TNM stage* (III/II/I) |
5.219 (2.276–11.965) | <0.001 | 4.445 (1.860–10.624) | 0.001 |
| Perineural invasion (no vs yes) |
0.412 (0.185–0.919) | 0.030 | 1.026 (0.406-2.596) | 0.956 |
| Vascular invasion (no vs yes) |
0.180 (0.084–0.386) | <0.001 | 0.587 (0.249–1.384) | 0.224 |
| P-TLS density (low vs high) |
6.597 (2.882–15.103) | <0.001 | 7.117 (2.478–20.437) | <0.001 |
| P-TLS maturation stage (SFL/PFL/E-TLS) |
0.508 (0.300–0.860) | 0.012 | 1.609 (0.802–3.231) | 0.181 |
| TSP (low vs high) |
0.126 (0.048–0.333) | <0.001 | 0.233 (0.080–0.679) | 0.008 |
| OS | ||||
| Sex (male vs female) |
0.538 (0.236-1.230) | 0.142 | ||
| Location (left/right colon/rectum) |
1.137 (0.679-1.906) | 0.625 | ||
| Age >60 vs ≤60 |
2.027 (0.953-4.315) | 0.067 | ||
| Tumor grade (G3/G2/G1) |
1.738 (0.902-3.348) | 0.098 | ||
| MMR (dMMR vs pMMR) |
0.419 (0.099-1.769) | 0.236 | ||
| TNM stage* (III/II/I) |
5.222 (2.278–11.975) | <0.001 | 4.276 (1.804–10.133) | 0.001 |
| Perineural invasion (no vs yes) |
0.410 (0.184–0.914) | 0.029 | 0.983 (0.370-2.380) | 0.893 |
| Vascular invasion (no vs yes) |
0.173 (0.081–0.372) | <0.001 | 0.554 (0.238–1.287) | 0.170 |
| P-TLS density (low vs high) |
6.628 (2.893–15.183) | <0.001 | 6.905 (2.423–19.678) | <0.001 |
| P-TLS maturation stage (SFL/PFL/E-TLS) |
0.505 (0.298–0.855) | 0.011 | 1.529 (0.766–3.049) | 0.228 |
| TSP (low vs high) |
0.125 (0.047–0.332) | <0.001 | 0.219 (0.075–0.639) | 0.005 |
MMR, mismatch repair; P-TLS, peritumoral tertiary lymphoid structure; TSP, tumor stroma percentage; E-TLS, early -TLS; TSP, PFL-TLS, primary follicle-like -TLS; SFL-TLS, secondary follicle-like -TLS; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval. *The 8th AJCC TNM staging system. The bold valuse was considered as statistically significant difference.